What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Drug: HB2198, a Tetravalent Bispecific Anti-CD19/CD20 Antibody with Dual Fc Domains administered via IV infusion on Day 1.”In the company’s words, NCT07439263 on ClinicalTrials.gov
- Tested for
- Systemic Lupus Erthematosus (SLE), Lupus Nephritis (LN), Extra-renal Lupus (ERL)
- Main trialPhase 1
- “Phase 1, single center, randomized, double blind, placebo controlled SAD study assessing safety, tolerability, PK, PD, and immunogenicity of HB2198 after a single IV infusion in healthy adults. Four dose levels will be explored with sentinel participants per cohort. Approximately 32 participants (6 HB2198:2 placebo per cohort) will be followed for \~2 months, with extended follow up if B-cell counts remain suppressed.”In the company’s words, NCT07439263 on ClinicalTrials.gov
Other drugs for Systemic Lupus Erthematosus (SLE)
- AnifrolumabAstraZeneca · Phase 3
- QL1074Qilu Pharmaceutical · Phase 3
- IanalumabNovartis · Phase 3
- Mycophenolate MofetilRoche · Phase 3
- ObinutuzumabRoche · Phase 3
- CenerimodViatris Innovation GmbH · Phase 3
Coming up1
- 24 Oct 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 14 Aug 2026 | Single Ascending Dose Study of HB2198 in Healthy Participants | |
| Phase 1Recruiting | 24 Oct 2027 | A Phase 1 Study of HB2198 in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026